Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non Operating Investment Income for 4 consecutive years, with $29000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Investment Income rose 152.73% to $29000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$7000.0, a 98.07% increase, with the full-year FY2024 number at -$68000.0, down 277.78% from a year prior.
  • Non Operating Investment Income was $29000.0 for Q3 2025 at Orchestra BioMed Holdings, up from -$21000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $1.4 million in Q4 2022 to a low of -$314000.0 in Q3 2022.
  • A 4-year average of $61928.6 and a median of -$18000.0 in 2024 define the central range for Non Operating Investment Income.
  • Peak YoY movement for Non Operating Investment Income: surged 193.31% in 2023, then plummeted 850.0% in 2025.
  • Orchestra BioMed Holdings' Non Operating Investment Income stood at $1.4 million in 2022, then plummeted by 121.59% to -$294000.0 in 2023, then surged by 81.29% to -$55000.0 in 2024, then surged by 152.73% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Non Operating Investment Income are $29000.0 (Q3 2025), -$21000.0 (Q2 2025), and -$15000.0 (Q1 2025).